J Quinn

Summary

Affiliation: Oregon Health and Science University
Country: USA

Publications

  1. pmc Biomarkers for Alzheimer's disease: showing the way or leading us astray?
    Joseph F Quinn
    Oregon Health and Science University and Portland VA Medical Center, Portland, OR 97239, USA
    J Alzheimers Dis 33:S371-6. 2013
  2. ncbi request reprint Beta-amyloid plaques induce neuritic dystrophy of nitric oxide-producing neurons in a transgenic mouse model of Alzheimer's disease
    J Quinn
    Portland Veteran s Affairs Medical Center, P3 R and D, 3710 SW US Veteran s Hospital Road, Portland, Oregon 97201, USA
    Exp Neurol 168:203-12. 2001
  3. ncbi request reprint Chronic melatonin therapy fails to alter amyloid burden or oxidative damage in old Tg2576 mice: implications for clinical trials
    Joseph Quinn
    Portland Veteran s Affairs Medical Center, Department of Neurology, Portland, OR 97239, USA
    Brain Res 1037:209-13. 2005
  4. pmc A copper-lowering strategy attenuates amyloid pathology in a transgenic mouse model of Alzheimer's disease
    Joseph F Quinn
    Portland Veterans Affairs Medical Center, P3 R and D, Portland, OR, USA
    J Alzheimers Dis 21:903-14. 2010
  5. pmc Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial
    Joseph F Quinn
    Department of Neurology, Oregon Health and Science University, Portland, OR 97239, USA
    JAMA 304:1903-11. 2010
  6. ncbi request reprint Antioxidants in Alzheimer's disease-vitamin C delivery to a demanding brain
    Joseph Quinn
    Department of Neurology, the Portland Veteran s Affairs Medical Center and Oregon Health and Science University, Portland OR 97201, USA
    J Alzheimers Dis 5:309-13. 2003
  7. ncbi request reprint Vascular dementia
    Joseph Quinn
    Department of Neurology, Oregon Health Science University, Portland, Oregon 97201, USA
    J Am Med Dir Assoc 4:S155-61. 2003
  8. ncbi request reprint Inflammation and cerebral amyloidosis are disconnected in an animal model of Alzheimer's disease
    Joseph Quinn
    Portland Veteran s Affairs Medical Center, and Department of Neurology, Oregon Health Sciences University, 97201, USA
    J Neuroimmunol 137:32-41. 2003
  9. ncbi request reprint A videotaped CIBIC for dementia patients: validity and reliability in a simulated clinical trial
    J Quinn
    Department of Neurology, Portland Veteran s Affairs Medical Center, P3 R and D, 3710 SW US Veterans Hospital Road, Portland, OR 97201, USA
    Neurology 58:433-7. 2002
  10. doi request reprint Copper in Alzheimer's disease: too much or too little?
    Joseph F Quinn
    Oregon Health and Science University, Portland VA Medical Center, Department of Neurology, Portland, OR 97239, USA
    Expert Rev Neurother 9:631-7. 2009

Detail Information

Publications47

  1. pmc Biomarkers for Alzheimer's disease: showing the way or leading us astray?
    Joseph F Quinn
    Oregon Health and Science University and Portland VA Medical Center, Portland, OR 97239, USA
    J Alzheimers Dis 33:S371-6. 2013
    ..This paper reviews several reports of biomarker studies which illustrate the great potential, for both good and ill, of biomarkers of Alzheimer's disease...
  2. ncbi request reprint Beta-amyloid plaques induce neuritic dystrophy of nitric oxide-producing neurons in a transgenic mouse model of Alzheimer's disease
    J Quinn
    Portland Veteran s Affairs Medical Center, P3 R and D, 3710 SW US Veteran s Hospital Road, Portland, Oregon 97201, USA
    Exp Neurol 168:203-12. 2001
    ..We conclude that beta-amyloid plaques induce neuritic dystrophy in cortical neurons containing NOS in this model of AD, and hypothesize that this finding may be relevant to the mechanism of beta-amyloid neurotoxicity in human AD...
  3. ncbi request reprint Chronic melatonin therapy fails to alter amyloid burden or oxidative damage in old Tg2576 mice: implications for clinical trials
    Joseph Quinn
    Portland Veteran s Affairs Medical Center, Department of Neurology, Portland, OR 97239, USA
    Brain Res 1037:209-13. 2005
    ..These findings diminish the possibility that melatonin will be useful for the treatment of established Alzheimer's disease...
  4. pmc A copper-lowering strategy attenuates amyloid pathology in a transgenic mouse model of Alzheimer's disease
    Joseph F Quinn
    Portland Veterans Affairs Medical Center, P3 R and D, Portland, OR, USA
    J Alzheimers Dis 21:903-14. 2010
    ..Our data suggests that controlled lowering of systemic copper may achieve anti-amyloid effects if initiated early in the disease process...
  5. pmc Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial
    Joseph F Quinn
    Department of Neurology, Oregon Health and Science University, Portland, OR 97239, USA
    JAMA 304:1903-11. 2010
    ..Epidemiological studies suggest that consumption of DHA is associated with a reduced incidence of Alzheimer disease. Animal studies demonstrate that oral intake of DHA reduces Alzheimer-like brain pathology...
  6. ncbi request reprint Antioxidants in Alzheimer's disease-vitamin C delivery to a demanding brain
    Joseph Quinn
    Department of Neurology, the Portland Veteran s Affairs Medical Center and Oregon Health and Science University, Portland OR 97201, USA
    J Alzheimers Dis 5:309-13. 2003
    ..717; p=0.016). We conclude that oral vitamin C supplements are delivered to the brain, and speculate that the increased CSF: plasma ratio of vitamin C in AD reflects increased antioxidant consumption by the AD brain...
  7. ncbi request reprint Vascular dementia
    Joseph Quinn
    Department of Neurology, Oregon Health Science University, Portland, Oregon 97201, USA
    J Am Med Dir Assoc 4:S155-61. 2003
  8. ncbi request reprint Inflammation and cerebral amyloidosis are disconnected in an animal model of Alzheimer's disease
    Joseph Quinn
    Portland Veteran s Affairs Medical Center, and Department of Neurology, Oregon Health Sciences University, 97201, USA
    J Neuroimmunol 137:32-41. 2003
    ..Further evidence against a causal relationship is seen in an unexpected trend to lower levels of beta amyloid after an inflammatory stimulus [lipopolysaccharide (LPS)]...
  9. ncbi request reprint A videotaped CIBIC for dementia patients: validity and reliability in a simulated clinical trial
    J Quinn
    Department of Neurology, Portland Veteran s Affairs Medical Center, P3 R and D, 3710 SW US Veterans Hospital Road, Portland, OR 97201, USA
    Neurology 58:433-7. 2002
    ..The global impression of a clinician is an Food and Drug Administration--mandated primary outcome measure for clinical trials in dementia. Reliability and validity of these measures are not well established...
  10. doi request reprint Copper in Alzheimer's disease: too much or too little?
    Joseph F Quinn
    Oregon Health and Science University, Portland VA Medical Center, Department of Neurology, Portland, OR 97239, USA
    Expert Rev Neurother 9:631-7. 2009
    ..The preclinical and clinical studies are discussed here in an effort to determine how to move forward with rational clinical trials focused on copper modulation...
  11. ncbi request reprint Asynchronous regional brain volume losses in presymptomatic to moderate AD
    J A Kaye
    Department of Neurology, Oregon Health and Science University, Portland, OR 97239, USA
    J Alzheimers Dis 8:51-6. 2005
    ..These regional and phase-specific volume changes form targets for monitoring disease-modifying therapies at clinically relevant, defined stages of dementia...
  12. ncbi request reprint Predictors of healthy brain aging
    M Gonzales Mc Neal
    Departments of Molecular and Medical Genetics, Oregon Health Sciences University, Portland 97201, USA
    J Gerontol A Biol Sci Med Sci 56:B294-301. 2001
    ..In this population, absence of apolipoprotein E-epsilon4 and male gender were associated with delayed onset, whereas estrogen use and education had no detectable effect on cognitive outcome...
  13. ncbi request reprint Brain volume loss in MCI predicts dementia
    D Erten-Lyons
    Department of Neurology, Oregon Health and Science University, Portland, OR, USA
    Neurology 66:233-5. 2006
    ..Rates of temporal horn volume change were significantly greater in the subjects with mild cognitive impairment who were developing dementia vs those who remained stable...
  14. pmc Serum vitamin D concentrations are associated with falling and cognitive function in older adults
    A Peterson
    Department of Neurology, Oregon Health and Science University and Portland Veteran Affairs Medical Center, Portland, OR 97239 USA
    J Nutr Health Aging 16:898-901. 2012
    ..Setting: Falls data were collected via weekly on-line surveys completed in the participants' homes. Yearly evaluations of motor and cognitive function were conducted in an out-patient setting of a large tertiary medical center...
  15. ncbi request reprint Natural history of cognitive decline in the old old
    D B Howieson
    Layton Aging and Alzheimer s Disease Center CR 131, Department of Neurology, Oregon Health and Science University, Portland, OR 97239 3098, USA
    Neurology 60:1489-94. 2003
    ..To prospectively examine the occurrence and outcome of cognitive decline in healthy, community-dwelling elders...
  16. ncbi request reprint Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression
    Maria Manczak
    Neurogenetics Laboratory, Neurological Sciences Institute, Oregon Health and Science University, 505 NW 185th Aveue, Beaverton, 97006, USA
    Hum Mol Genet 15:1437-49. 2006
    ..These findings suggest that early mitochondrially targeted therapeutic interventions may be effective in delaying AD progression in elderly individuals and in treating AD patients...
  17. ncbi request reprint Gene expression profiles of transcripts in amyloid precursor protein transgenic mice: up-regulation of mitochondrial metabolism and apoptotic genes is an early cellular change in Alzheimer's disease
    P Hemachandra Reddy
    Neurogenetics Laboratory, Neurological Sciences Institute, Oregon Health and Science University, Beaverton, OR 97006, USA
    Hum Mol Genet 13:1225-40. 2004
    ..These findings have important implications for understanding the mechanism of Abeta toxicity in AD and for developing therapeutic strategies for AD...
  18. pmc Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial
    Robert C Green
    Department of Neurology, Boston University School of Medicine, 72 E Concord St, L 320, Boston, MA 02118, USA
    JAMA 302:2557-64. 2009
    ..Tarenflurbil, a selective Abeta(42)-lowering agent, demonstrated encouraging results on cognitive and functional outcomes among mildly affected patients in an earlier phase 2 trial...
  19. pmc Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer's disease
    David A Wolk
    Department of Neurology, University of Pennsylvania, Philadelphia, PA 19104, USA
    Proc Natl Acad Sci U S A 107:10256-61. 2010
    ....
  20. ncbi request reprint apoE isoforms and measures of anxiety in probable AD patients and Apoe-/- mice
    Jennifer Robertson
    Department of Behavioral Neuroscience, L470, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA
    Neurobiol Aging 26:637-43. 2005
    ..Consistent with the mouse data, male and female PRAD patients with epsilon4/epsilon4 showed higher anxiety scores than those with epsilon3/epsilon3. We conclude that human apoE isoforms have differential effects on measures of anxiety...
  21. ncbi request reprint Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins
    Sandip Ray
    Satoris, Inc, 2686 Middlefield Road, Suite E, Redwood City, California 94063, USA
    Nat Med 13:1359-62. 2007
    ..Biological analysis of the 18 proteins points to systemic dysregulation of hematopoiesis, immune responses, apoptosis and neuronal support in presymptomatic Alzheimer's disease...
  22. pmc Free radical-mediated damage to brain in Alzheimer's disease and its transgenic mouse models
    Joshua A Sonnen
    Department of Pathology and of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, USA
    Free Radic Biol Med 45:219-30. 2008
    ..Future efforts in preclinical models and ultimately clinical trials are needed to define optimally effective agents and combinations, doses, and timing to suppress safely this facet of AD...
  23. ncbi request reprint Nutritional biomarkers in Alzheimer's disease: the association between carotenoids, n-3 fatty acids, and dementia severity
    Wei Wang
    Department of Medicine, Oregon Health and Science University, Portland, OR 97239, USA
    J Alzheimers Dis 13:31-8. 2008
    ..These findings suggest targeting multiple specific nutrients, lutein, beta-carotene, and DHA in strategies to slow the rate of cognitive decline...
  24. pmc CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases
    Jing Zhang
    Department of Pathology, University of Washington School of Medicine, Seattle, WA 98104, USA
    Am J Clin Pathol 129:526-9. 2008
    ..This first large-scale validation of a proteomic-discovered MAP suggests a panel of 8 CSF proteins that are highly effective at identifying PD and moderately effective at identifying AD...
  25. pmc Biomarkers for cognitive impairment and dementia in elderly people
    Joshua A Sonnen
    Department of Pathology, Division of Neuropathology, University of Washington, Seattle, WA 98104, USA
    Lancet Neurol 7:704-14. 2008
    ..An approach that efficiently combines independent information from risk-factor assessment, neuroimaging measures, and biomarkers might soon guide clinicians in the early diagnosis and management of cognitive impairment in elderly people...
  26. pmc Multiple SNPs within and surrounding the apolipoprotein E gene influence cerebrospinal fluid apolipoprotein E protein levels
    Lynn M Bekris
    Geriatric Research, Education, and Clinical Center GRECC, VA Puget Sound Health Care System, Seattle, WA 98108, USA
    J Alzheimers Dis 13:255-66. 2008
    ..Further investigation of the genetic influence of these loci on apoE expression levels in the central nervous system is likely to provide new insight into apoE regulation as well as AD pathogenesis...
  27. ncbi request reprint Peripheral F2-isoprostanes and F4-neuroprostanes are not increased in Alzheimer's disease
    Thomas J Montine
    Department of Pathology, Vanderbilt University Medical Center, Nashville, TN 37232, USA
    Ann Neurol 52:175-9. 2002
    ..These results should guide the organization of clinical trials now being planned for patients with Alzheimer's disease...
  28. pmc Evaluation of coenzyme Q as an antioxidant strategy for Alzheimer's disease
    Teri L Wadsworth
    Department of Neurology, Oregon Health and Science University, Portland, OR 97239 3098, USA
    J Alzheimers Dis 14:225-34. 2008
    ..Our results suggest that oral CoQ may be a viable antioxidant strategy for neurodegenerative disease. Our data supports a trial of CoQ in an animal model of AD in order to determine whether a clinical trial is warranted...
  29. ncbi request reprint Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders
    Fadi Abdi
    Applied Biosystems, Framingham, MA, USA
    J Alzheimers Dis 9:293-348. 2006
    ....
  30. ncbi request reprint Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition
    Elaine R Peskind
    VA Puget Sound Health Care System, Mental Illness Research, Education, and Clinical Center, Seattle, WA 98108, USA
    Arch Neurol 63:936-9. 2006
    ..Normal aging and the presence of the apolipoprotein E (APOE*4) allele are the most important known risk factors for Alzheimer disease...
  31. ncbi request reprint Lipid peroxidation in aging brain and Alzheimer's disease
    Thomas J Montine
    Department of Pharmacology, Pathology, and Medicine and the Vanderbilt Brain Institute, Vanderbilt University Medical Center, Nashville, TN, USA
    Free Radic Biol Med 33:620-6. 2002
    ....
  32. ncbi request reprint Prevention of age-related spatial memory deficits in a transgenic mouse model of Alzheimer's disease by chronic Ginkgo biloba treatment
    Robert W Stackman
    Department of Behavioral Neuroscience, Oregon Health and Science University, Portland, OR 97239 3098, USA
    Exp Neurol 184:510-20. 2003
    ..These data indicate that chronic Ginkgo biloba treatment can block an age-dependent decline in spatial cognition without altering Abeta levels and without suppressing protein oxidation in a transgenic mouse model of AD...
  33. ncbi request reprint Suppression of longitudinal increase in CSF F2-isoprostanes in Alzheimer's disease
    Joseph F Quinn
    Department Neurology, Oregon Health and Sciences University, Portland, OR, USA
    J Alzheimers Dis 6:93-7. 2004
    ....
  34. ncbi request reprint Measurement of gelatinase B (MMP-9) in the cerebrospinal fluid of patients with vascular dementia and Alzheimer disease
    John C Adair
    Department of Neurology, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA
    Stroke 35:e159-62. 2004
    ....
  35. ncbi request reprint F2-isoprostanes in Alzheimer and other neurodegenerative diseases
    Thomas J Montine
    Department of Pathology, University of Washington, Seattle, WA 98104, USA
    Antioxid Redox Signal 7:269-75. 2005
    ..These results indicate that brain lipid peroxidation is a potential therapeutic target early in the course of AD, and that CSF F2-IsoPs may aid in the assessment of antioxidant experimental therapeutics and laboratory diagnosis of AD...
  36. ncbi request reprint Reduced CSF PLTP activity in Alzheimer's disease and other neurologic diseases; PLTP induces ApoE secretion in primary human astrocytes in vitro
    Simona Vuletic
    Department of Medicine, Northwest Lipid Metabolism and Diabetes Research Laboratories, University of Washington, Seattle, Washington 98109 4517, USA
    J Neurosci Res 80:406-13. 2005
    ..The findings of reduced PLTP activity in AD CSF, and the observation that PLTP can influence apoE secretion in astrocytes suggest a potential link between alterations in the brain lipid metabolism and AD pathogenesis...
  37. ncbi request reprint Mouse cerebral prostaglandins, but not oxidative damage, change with age and are responsive to indomethacin treatment
    Kathleen S Montine
    Department of Pathology, Vanderbilt University Medical Center, C3321 A Medical Center North, Nashville, TN 37232, USA
    Brain Res 930:75-82. 2002
    ..These results suggest that indomethacin may influence the initiation of AD by reducing cerebral PG elevation that may occur in middle age, but that it is unlikely to have a direct effect on levels of oxidative damage...
  38. ncbi request reprint Quantitative in vivo biomarkers of oxidative damage and their application to the diagnosis and management of Alzheimer's disease
    Thomas J Montine
    Department of Pathology, University of Washington, Seattle, WA 98104, USA
    J Alzheimers Dis 8:359-67. 2005
    ..In addition, measurement of CSF F2-IsoPs can increase the accuracy of laboratory-based classification of geriatric dementias, and have been used to assess objectively the response to anti-oxidant interventions in AD...
  39. ncbi request reprint Chronic dietary alpha-lipoic acid reduces deficits in hippocampal memory of aged Tg2576 mice
    Joseph F Quinn
    Portland Veterans Affairs Medical Center, P3 R and D Portland, OR, United States
    Neurobiol Aging 28:213-25. 2007
    ..These data indicate that chronic dietary ALA can reduce hippocampal-dependent memory deficits of Tg2576 mice without affecting beta-amyloid levels or plaque deposition...
  40. ncbi request reprint Safety and acceptability of the research lumbar puncture
    Elaine R Peskind
    VA Puget Sound Health Care System, Mental Illness Research, Education and Clinical Center MIRECC, University of Washington School of Medicine, Seattle, WA 98108, USA
    Alzheimer Dis Assoc Disord 19:220-5. 2005
    ....
  41. ncbi request reprint Proteomic determination of widespread detergent-insolubility including Abeta but not tau early in the pathogenesis of Alzheimer's disease
    Randall L Woltjer
    Department of Pathology, Division of Neuropathology, University of Washington, Seattle, WA, USA
    FASEB J 19:1923-5. 2005
    ..These results are consistent with the amyloid hypothesis of AD and extend it to include widespread protein insolubility, not exclusively Abeta insolubility, early in AD pathogenesis even before the onset of clinical dementia...
  42. pmc Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease
    Adam S Fleisher
    University of California, San Diego, La Jolla, CA 92037, USA
    Arch Neurol 65:1031-8. 2008
    ..To evaluate the safety, tolerability, and amyloid beta (Abeta) response to the gamma-secretase inhibitor LY450139 in Alzheimer disease...
  43. ncbi request reprint Quantitative proteomic analysis of age-related changes in human cerebrospinal fluid
    Jing Zhang
    Division of Neuropathology, University of Washington School of Medicine, Box 359635, Harborview Medical Center, Seattle, WA 98104, USA
    Neurobiol Aging 26:207-27. 2005
    ..These data not only expand substantially our current knowledge regarding human CSF proteins, but also supply the necessary information to appropriately interpret protein biomarkers of age-related neurodegenerative diseases...
  44. ncbi request reprint Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases
    Kathleen S Montine
    Department of Pathology, University of Washington, Harborview Medical Center, Box 359791, 325 9th Ave, Seattle, WA 98104, USA
    Chem Phys Lipids 128:117-24. 2004
    ..These results indicate that brain lipid peroxidation is a potential therapeutic target early in the course of AD and HD, that CSF IsoPs may aid in the assessment of anti-oxidant experimental therapeutics and laboratory diagnosis of AD...
  45. ncbi request reprint Identification of glycoproteins in human cerebrospinal fluid with a complementary proteomic approach
    Sheng Pan
    Department of Pathology, University of Washington, Seattle, Washington 98104, USA
    J Proteome Res 5:2769-79. 2006
    ..This investigation, for the first time, not only categorized many glycoproteins in human CSF but also expanded the existing overall CSF protein database...
  46. ncbi request reprint Retirement patterns from career employment
    Kevin E Cahill
    Analysis Group, Inc, 111 Huntington Avenue, 10th Floor, Boston, MA 02199, USA
    Gerontologist 46:514-23. 2006
    ..This article investigates how older Americans leave their career jobs and estimates the extent of intermediate labor force activity (bridge jobs) between full-time work on a career job and complete labor-force withdrawal...
  47. ncbi request reprint Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease
    Jing Zhang
    Department of Pathology, University of Washington School of Medicine, Seattle, WA 98104, USA
    J Alzheimers Dis 7:125-33; discussion 173-80. 2005
    ....

Research Grants1

  1. Copper Complexing with Tetrathiomolybdate in a Murine Model of Alzheimers Disease
    Joseph Quinn; Fiscal Year: 2007
    ..These are the critical pieces of information for determining if TM should be evaluated in clinical trials for either the prevention or the treatment of Alzheimer's disease. ..